Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.56 |
| ▸ | ITGAV | P06756 | 1/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.56 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13593303 | 0.89 | ITGB3 (0.55) | NR1H4ITGB3ITGA2BKMT2ATRPV1 | |
| SCHEMBL10102714 | 0.85 | NR1H4 (0.72) | NR1H4ITGB3ITGB1ITGAVITGA2B | |
| SCHEMBL13618528 | 0.85 | MEN1 (0.72) | NR1H4ITGB3ITGB1ITGAVITGA2B | |
| SCHEMBL13593586 | 0.85 | NR1H4 (0.58) | NR1H4ITGB3ITGB1ITGAVITGA2B | |
| SCHEMBL14595003 | 0.85 | ITGB3 (0.59) | NR1H4ITGB3ITGB1ITGAVITGA2B | |
| SCHEMBL13814818 | 0.85 | NR1H4 (0.58) | NR1H4ITGB3ITGB1ITGAVITGA2B | |
| SCHEMBL2061403 | 0.84 | NR1H4 (0.71) | NR1H4MEN1KMT2ACYSLTR1TRPV1 | |
| SCHEMBL14088989 | 0.82 | NR1H4 (0.81) | NR1H4MEN1KMT2AFFAR1CYSLTR1 | |
| SCHEMBL1468045 | 0.81 | NR1H4 (0.58) | NR1H4ITGB3ITGB1ITGAVITGA2B | |
| SCHEMBL5659023 | 0.81 | NPC1 (0.66) | NR1H4MEN1KMT2ATP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148328-B2 | Salicylanilides enhance oral delivery of therapeutic peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110183889-A1 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-07-28 | — | — | US | disclosed |
| CN-101842101-A | Salicylanilide modified peptides for use as oral therapeutics | UNIV CALIFORNINA | 2010-09-22 | — | — | CN | disclosed |
| EP-2182956-A2 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | The Regents of the University of California (US) | 2010-05-12 | — | — | EP | disclosed |
| CN-101522207-A | Salicylanilides enhance oral delivery of therapeutic peptides | UNIV CALIFORNINA (US) | 2009-09-02 | — | — | CN | disclosed |
| US-7553872-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553872-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090163408-A1 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-25 | — | — | US | disclosed |
| EP-2049137-A2 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | The Regents of the University of California (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009032749-A2 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNINA (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2008021088-A2 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNINA (US) | 2008-02-21 | — | — | WO | disclosed |
| US-7071214-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163408-A1 | SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES | DNPEP, NGLY1, VIP | NR1H4 1406/4885ITGB3 4850/4885ITGB1 4884/4885 |
| US-20110183889-A1 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | DNPEP, PTMS, NGLY1 | NR1H4 3888/4885ITGB3 4839/4885ITGB1 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.